Skip to content Skip to sidebar Skip to footer
Subscribe Now
Weekly Snapshot
PharmaShots Weekly Snapshots (Jun 30, 2025 – Jul 04, 2025)    
This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, and Biosimilar. Check out our full report below:  Neurocrine Reports Data From KINECT-HD Study Evaluating INGREZZA in Huntington’s Disease (HD)  Read More: Neurocrine  UCB Reports the P-III Data of Fenfluramine in CDKL5 Deficiency Disorder (CDD) Patients  Read More: UCB  …
July 4, 20250Comments
THOUGHTSPOT
Is Addiction Hereditary?
When you think about addiction, you likely wonder if your family history puts you at risk. The answer isn't straightforward, genetics account for 40-60% of addiction vulnerability, while your environment shapes the rest. Your DNA influences how your brain responds to substances, but it doesn't seal your fate. Understanding this genetic component reveals why addiction…
July 4, 20250Comments
News
Biocon Biologics Receives the EC’s Approval for Vevzuo and Evfraxy (Biosimilars, Xgeva and Prolia)
Shots: The EC has approved Vevzuo & Evfraxy, biosimilar versions of Amgen’s Xgeva & Prolia (denosumab) following the CHMP positive opinion in Apr 2025 Approval was based on the comprehensive clinical data, which showed comparable PK, safety, efficacy & immunogenicity of Vevzuo & Evfraxy to the reference product Vevzuo prevents SREs in adults with bone-involved malignancies…
July 4, 20250Comments
Vertex Pharmaceuticals
News
Vertex Presents Long-Term CLIMB Trial Program Data of Casgevy (Exagamglogene Autotemcel) to Treat Hemoglobinopathies at EHA 2025
Shots: The global P-I/II/III (CLIMB-121 & 111) trials assessed Casgevy in sev. SCD & TDT pts (12–35 yrs), with 2yr. post-infusion follow-up, after which pts entered the ongoing 15yr. CLIMB-131 trial, with SCD pts followed for >5.5yrs & TDT for >6yrs. In SCD, 43/45 pts were VOC-free for ≥12mos., with mean VOC-free duration of 35mos.…
July 4, 20250Comments
News
Brii Biosciences Enters a Licensing Deal with Joincare Pharmaceutical for BRII-693 to Treat Bacterial Infections
Brii Biosciences has entered into a license & technology transfer agreement with Joincare to develop & commercialize BRII-693 in the Greater China region As per the deal, Joincare will handle development, regulatory activities & commercialization of BRII-693 in Greater China in exchange for an upfront payment as well as development & commercial milestones, with net…
July 4, 20250Comments
News
Johnson & Johnson Seeks the EC’s Approval for Akeega to Treat Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The EMA has received an application for label expansion of Akeega (niraparib & abiraterone acetate tablet) + prednisone/prednisolone to treat adults with mHSPC & HRR gene alterations Submission was backed by P-III (AMPLITUDE) trial assessing Akeega + prednisone/ prednisolone + ADT vs PBO/AAP + ADT in 696 pts with deleterious germline or somatic HRR gene-altered…
July 4, 20250Comments
20 Innovative Digital Therapeutics Companies of 2025
TOP 20
20 Innovative Digital Therapeutics Companies of 2025 
Shots:   The integration of innovative technologies in healthcare, such as digital health platforms and AI-enabled applications, is transforming the way diseases are detected, diagnosed, treated, and prevented  The global Digital Health market is expected to reach $197.88B in 2025 and grow at a CAGR of 6.88%, reaching $258.25B by 2029  PharmaShots presents a concise report…
July 3, 20250Comments